Cancer
Lung cancer in Hefei
合肥 肺癌
6 hospitals in Hefei
Order: papers led on lung cancer, 2021–2025, then A–Z. Research activity, not a rating of care.
Only hospitals listed for lung cancer: those with enough papers or registered trials on it in the records this site uses. Other hospitals in Hefei may also treat it. “Papers led” counts English-language PubMed papers whose first or last author lists the hospital first.
- 82 papers ledNo open trial led
- 68 papers led
- 28 papers ledNo open trial led
- 16 papers ledNo open trial led
- 1 paper led
- 1 paper ledNo open trial led
Lung cancer in every city Hefei on the disease page, with the national map
open trials on lung cancer with a hospital in Hefei
Recruiting, not yet recruiting, or by invitation, as registered on ClinicalTrials.gov on 18 Nov 2026, with a listed hospital in Hefei as lead sponsor or study site. 3 of them are led by a hospital in Hefei. Check the registry for the current status. Whether someone can take part is decided by the study team.
Only trials registered on ClinicalTrials.gov are counted. Trials registered only in China’s own registry (ChiCTR) are not.
- RecruitingSymbiotic-Lung-01 : A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
- Phase
- Phase 3
- Started
- 2026-01
- Posted
- Registry
- NCT07222566
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 36 listed hospitals as study sitesBeijing, Changchun, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Hangzhou, Hefei, Jiangmen, Jinan, Linyi, Luoyang, Nanchang, Nanjing, Nanning, Shanghai, Taiyuan, Taizhou, Wenzhou, Wuhan, Xiangyang, Xinxiang, Yangzhou, Zhengzhou
- RecruitingA Phase II Clinical Study to Evaluate HLX43 in Combination With Serplulimab in Subjects With Advanced Lung Cancer
- Phase
- Phase 2
- Started
- 2026-02
- Posted
- Registry
- NCT07253142
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 9 listed hospitals as study sitesFuzhou, Guangzhou, Harbin, Hefei, Nanning, Shanghai, Wuhan, Xinxiang, Xuzhou
- RecruitingRC148 Plus Platinum-Based Chemotherapy vs Tislelizumab Plus Platinum-Based Chemotherapy for First-Line Squamous Non-Small Cell Lung Cancer (sqNSCLC)
- Phase
- Phase 3
- Started
- 2026-04
- Posted
- Registry
- NCT07416474
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 66 listed hospitals as study sitesAnyang, Beijing, Changchun, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Guilin, Hangzhou, Harbin, Hefei, Jiangmen, Jinan, Kunming, Lanzhou, Linyi, Luoyang, Nanchang, Nanjing, Nanning, Qingdao, Shanghai, Shenyang, Shenzhen, Shijiazhuang, Suzhou, Taiyuan, Taizhou, Tianjin, Urumqi, Wenzhou, Wuhan, Xiamen, Xiangyang, Xinxiang, Xuzhou, Yantai, Yinchuan, Zhengzhou, Zhuhai
- RecruitingA Study to Evaluate the Efficacy and Safety of Divarasib Compared With Investigator's Choice of Immunotherapy or Observation in Participants With Resected Stage II-III KRAS G12C-Positive Non-Small Cell Lung Cancer (NSCLC)
- Phase
- Phase 3
- Started
- 2026-10
- Posted
- Registry
- NCT07541170
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 16 listed hospitals as study sitesBeijing, Changchun, Chengdu, Foshan, Guangzhou, Hangzhou, Hefei, Jinan, Nanchang, Shenzhen, Suzhou, Taizhou, Tianjin
- RecruitingA Clinical Trial of Calderasib (MK-1084) and Durvalumab in People With Non-Small Cell Lung Cancer (MK-1084-015/KANDLELIT-015)
- Phase
- Phase 3
- Started
- 2026-06
- Posted
- Registry
- NCT07554339
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 26 listed hospitals as study sitesBeijing, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Guilin, Hangzhou, Hefei, Jinan, Nanjing, Nanning, Shanghai, Shijiazhuang, Taiyuan, Taizhou, Urumqi, Wenzhou, Wuhan, Xiamen
- RecruitingMetronomic Oral Paclitaxel Plus PD-1/ PD-L1 Inhibitor Maintenance in Advanced Lung Cancer (PULSE Study)
- Phase
- Phase 4
- Started
- 2026-07
- Posted
- Registry
- NCT07744698
Age 18 years to 75 years (registered criteria)
Led by Anhui Provincial Cancer Hospital; 1 listed hospital as study siteHefei
- RecruitingctDNA-driven Adaptive Proton Craniospinal Irradiation in Non-Small Cell Lung Cancer With Leptomeningeal Metastasis After Resistance to Third-Generation TKIs in the Consolidation Phase
- Phase
- N/A
- Started
- 2026-08
- Posted
- Registry
- NCT07751536
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 2 listed hospitals as study sitesHefei
- RecruitingA Multi Tumor, Open Phase I Clinical Study on the Progression of First-line Anti-tumor Therapy Using Cardonizumab Combined With Pulsed Low-dose Rate External Irradiation (PLDR)
- Phase
- Phase 1
- Started
- 2025-09
- Posted
- Registry
- NCT06232083
Age 18 years to 75 years (registered criteria)
Led by First Affiliated Hospital of USTCHefei
- RecruitingSafety and Efficacy of BNT327, an Investigational Therapy in Combination With Chemotherapy for Patients With Untreated Small-cell Lung Cancer
- Phase
- Phase 3
- Started
- 2025-02
- Posted
- Registry
- NCT06712355
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 29 listed hospitals as study sitesBeijing, Bengbu, Changchun, Chongqing, Fuzhou, Guangzhou, Hangzhou, Harbin, Hefei, Jinan, Linyi, Nanchang, Shanghai, Shantou, Shijiazhuang, Suzhou, Taiyuan, Taizhou, Wenzhou, Wuhan, Xiangyang, Xinxiang, Yangzhou, Zhengzhou
- RecruitingThis is a Study to Learn About How the Combination of the Study Medicines Sigvotatug Vedotin Plus Pembrolizumab Works in People With Non-small Cell Lung Cancer With High Levels of PD-L1.
- Phase
- Phase 3
- Started
- 2025-07
- Posted
- Registry
- NCT06758401
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 28 listed hospitals as study sitesBeijing, Changsha, Changzhou, Chengdu, Fuzhou, Guangzhou, Hangzhou, Harbin, Hefei, Jinan, Linyi, Luoyang, Nanchang, Nanjing, Nanning, Shanghai, Taizhou, Tianjin, Wenzhou, Wuhan, Xi'an, Xuzhou, Zhengzhou
- RecruitingA Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Participants With Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer
- Phase
- Phase 3
- Started
- 2025-10
- Posted
- Registry
- NCT06793215
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 19 listed hospitals as study sitesBeijing, Bengbu, Changsha, Chengdu, Guangzhou, Hangzhou, Harbin, Hefei, Jinan, Kunming, Nanchang, Nantong, Shanghai, Shantou, Wuhan
- RecruitingClinical Effectiveness and Safety of Trastuzumab Deruxtecan (T-DXd) in Chinese Patients With HER2m NSCLC (RERUN)
- Phase
- Not given
- Started
- 2025-02
- Posted
- Registry
- NCT06809764
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 30 listed hospitals as study sitesBeijing, Fuzhou, Guangzhou, Hangzhou, Hefei, Jinan, Nanchang, Nanjing, Nanning, Nantong, Qingdao, Shanghai, Shenyang, Shenzhen, Shijiazhuang, Wuhan, Xiamen, Zhengzhou
- RecruitingTislelizumab Combined With Chemotherapy and Relayed Radiotherapy in First-line Treatment of ES-SCLC
- Phase
- Phase 2
- Started
- 2025-02
- Posted
- Registry
- NCT06838208
Age 18 years to Not stated (registered criteria)
Led by Anhui Provincial Cancer Hospital; 1 listed hospital as study siteHefei
- RecruitingReal World Clinical Outcomes of Resected ALK-Positive Early Stage NSCLC Patients Treated With Alectinib as Adjuvant Therapy
- Phase
- Not given
- Started
- 2025-04
- Posted
- Registry
- NCT06862869
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 35 listed hospitals as study sitesBeijing, Changsha, Chengdu, Chongqing, Dalian, Fuzhou, Guangzhou, Hangzhou, Harbin, Hefei, Jiangmen, Jinan, Lanzhou, Nanchang, Nanjing, Nantong, Shanghai, Shenzhen, Shijiazhuang, Taiyuan, Taizhou, Wuhan, Wuxi, Xi'an, Yinchuan, Zhanjiang, Zunyi
- RecruitingA Study of Adagrasib Plus Pembrolizumab Plus Chemotherapy vs. Placebo Plus Pembrolizumab Plus Chemotherapy in Participants With Previously Untreated Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation (KRYSTAL-4)
- Phase
- Phase 3
- Started
- 2025-04
- Posted
- Registry
- NCT06875310
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 39 listed hospitals as study sitesBeijing, Bengbu, Changchun, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Hangzhou, Harbin, Hefei, Jinan, Linyi, Nanchang, Nanjing, Nanning, Shanghai, Shantou, Shenyang, Shenzhen, Shijiazhuang, Suzhou, Taiyuan, Taizhou, Tianjin, Wuhan, Xiamen, Xinxiang, Yangzhou
- RecruitingA Clinical Study to Investigate the Efficacy and Safety of an Investigational Combination Therapy With BNT324 and BNT327 in Patients With Advanced Lung Cancer
- Phase
- Phase 1/Phase 2
- Started
- 2025-05
- Posted
- Registry
- NCT06892548
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 25 listed hospitals as study sitesBeijing, Changchun, Chengdu, Fuzhou, Guangzhou, Hangzhou, Hefei, Jinan, Linyi, Nanchang, Nanjing, Nanning, Xi'an, Xiamen, Xiangyang, Xinxiang, Xuzhou, Yichang, Zhengzhou
- RecruitingStudy of Trastuzumab Deruxtecan, Pembrolizumab, and Platinum-based Chemotherapy in First-line HER2 Overexpressing Non-small Cell Lung Cancer
- Phase
- Phase 3
- Started
- 2025-10
- Posted
- Registry
- NCT06899126
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 28 listed hospitals as study sitesBeijing, Changchun, Changsha, Chengdu, Chongqing, Guangzhou, Hangzhou, Harbin, Hefei, Jinan, Linyi, Nanchang, Nanjing, Shanghai, Shenyang, Taiyuan, Tianjin, Wuhan, Xiangyang, Zhengzhou
- RecruitingAcupuncture Combined With PD-1/PD-L1 Inhibitors for Advanced Lung Cancer
- Phase
- N/A
- Started
- 2025-06
- Posted
- Registry
- NCT06926140
Age 18 years to 75 years (registered criteria)
Led by Guang'anmen Hospital; 1 listed hospital as study siteBeijing, Hefei
- RecruitingA Clinical Trial to Test if an Investigational Combination Therapy With BNT326 and BNT327 is Safe and Potentially Beneficial for People With Advanced Non-small Cell Lung Cancer (NSCLC)
- Phase
- Phase 1/Phase 2
- Started
- 2025-09
- Posted
- Registry
- NCT07111520
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 22 listed hospitals as study sitesChangchun, Chengdu, Chongqing, Fuzhou, Guangzhou, Hefei, Jinan, Nanchang, Qingdao, Shanghai, Shijiazhuang, Suzhou, Tianjin, Wuhan, Xiangyang, Xinxiang, Xuzhou, Yangzhou
- RecruitingA Prospective Cohort Study of Zorifertinib as a First-line Treatment in Patients With Epidermal Growth Factor Receptor-mutant Advanced Non-small Cell Lung Cancer With Central Nervous System (CNS) Metastases
- Phase
- Not given
- Started
- 2025-12
- Posted
- Registry
- NCT07143045
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 24 listed hospitals as study sitesChangchun, Changsha, Chengdu, Chongqing, Foshan, Fuzhou, Guangzhou, Harbin, Hefei, Kunming, Nanchang, Nanjing, Nanning, Qingdao, Shenyang, Shenzhen, Taiyuan, Tianjin, Wuhan, Xiamen, Yangzhou, Zhengzhou
- RecruitingA Study to Learn About the Study Medicine Called PF-08046054/SGN-PDL1V Versus Docetaxel in Adult Participants With Previously-Treated Programmed Cell Death Ligand 1 (PD-L1) Positive Non-Small-Cell Lung Cancer (NSCLC)
- Phase
- Phase 3
- Started
- 2025-09
- Posted
- Registry
- NCT07144280
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 23 listed hospitals as study sitesBeijing, Changsha, Changzhou, Chengdu, Chongqing, Fuzhou, Guangzhou, Hangzhou, Harbin, Hefei, Jinan, Nanchang, Nanjing, Nanning, Shanghai, Taizhou, Wuhan, Xi'an, Xuzhou, Zhengzhou
- RecruitingA Phase 2 Clinical Study of Combination Therapy With ABSK043 and Glecirasib
- Phase
- Phase 2
- Started
- 2025-09
- Posted
- Registry
- NCT07164170
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 15 listed hospitals as study sitesBeijing, Chengdu, Fuzhou, Guangzhou, Harbin, Hefei, Nanjing, Nanning, Shanghai, Shenyang, Wuhan, Xi'an, Zhengzhou
- RecruitingA Study of YL202 in Combination With Other Anti-tumor Therapies in Patients With Advanced Solid Tumors
- Phase
- Phase 1/Phase 2
- Started
- 2025-09
- Posted
- Registry
- NCT07169994
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 14 listed hospitals as study sitesAnyang, Chengdu, Fuzhou, Guangzhou, Harbin, Hefei, Luoyang, Nanchang, Nanjing, Shanghai, Shenyang, Taiyuan, Tianjin, Xiangyang
- RecruitingA Phase 3 Study of Sunvozertinib Versus Placebo as Adjuvant Therapy in Patients With Early-Stage Non-Small Cell Lung Cancer Harboring EGFR Exon 20 Insertion Mutations or PACC Mutations After Radical Surgery
- Phase
- Phase 3
- Started
- 2025-12
- Posted
- Registry
- NCT07182682
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 47 listed hospitals as study sitesBeijing, Changchun, Changsha, Chengdu, Fuzhou, Guangzhou, Hangzhou, Harbin, Hefei, Jinan, Kunming, Nanjing, Nanning, Shanghai, Shenyang, Taiyuan, Taizhou, Tianjin, Wuhan, Xi'an, Xuzhou, Zhengzhou
- RecruitingStudy to Evaluate Efficacy and Safety of Firmonertinib Compared With Investigator's Choice of EGFR Inhibitor as First-Line Treatment in Participants Who Have Locally Advanced or Metastatic NSCLC With EGFR P-Loop and Alpha C-Helix Compressing (PACC) Uncommon Mutations
- Phase
- Phase 3
- Started
- 2025-12
- Posted
- Registry
- NCT07185997
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 45 listed hospitals as study sitesBeijing, Changsha, Chengdu, Chongqing, Dalian, Foshan, Fuzhou, Guangzhou, Hangzhou, Harbin, Hefei, Hohhot, Jinan, Kunming, Linyi, Luoyang, Nanchang, Nanjing, Nanning, Nantong, Qingdao, Shanghai, Shantou, Shenyang, Shijiazhuang, Taiyuan, Tianjin, Weifang, Wuhan, Xinxiang, Zhengzhou
- RecruitingA Clinical Study of Calderasib (MK-1084) and Other Treatments for Participants With Non-Small Cell Lung Cancer (MK-1084-007/KANDLELIT-007)
- Phase
- Phase 3
- Started
- 2025-10
- Posted
- Registry
- NCT07190248
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 29 listed hospitals as study sitesBeijing, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Hangzhou, Hefei, Linyi, Nanchang, Nanjing, Nanning, Shanghai, Taiyuan, Taizhou, Wuhan, Xi'an, Xiamen, Zhengzhou
- RecruitingTo Explore the Safety and Efficacy of Hypervision Proton Surgery for Early-stage Non-small Cell Lung Cancer
- Phase
- N/A
- Started
- 2025-09
- Posted
- Registry
- NCT07195084
Age 18 years to Not stated (registered criteria)
Led by Anhui Provincial Cancer Hospital; 1 listed hospital as study siteHefei
- RecruitingA Study Comparing TAK-928 With Docetaxel in Adults With Non-Small Cell Lung Cancer
- Phase
- Phase 3
- Started
- 2025-11
- Posted
- Registry
- NCT07217301
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 35 listed hospitals as study sitesBeijing, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Hangzhou, Harbin, Hefei, Jinan, Kunming, Luzhou, Nanchang, Nanjing, Shanghai, Shenyang, Shijiazhuang, Tianjin, Wenzhou, Xi'an, Xinxiang, Xuzhou, Zhengzhou
- RecruitingA Study of ZL-1310 Versus Investigator's Choice of Therapy in Participants With Relapsed Small Cell Lung Cancer (DLLEVATE)
- Phase
- Phase 3
- Started
- 2025-11
- Posted
- Registry
- NCT07218146
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 23 listed hospitals as study sitesBeijing, Changchun, Changsha, Chengdu, Fuzhou, Guangzhou, Hangzhou, Harbin, Hefei, Jinan, Linyi, Nanchang, Nanjing, Nanning, Shanghai, Shijiazhuang, Taizhou, Wuhan, Xi'an, Xiamen, Zhengzhou
- RecruitingA Study of ZL-1310 in Subjects With Small Cell Lung Cancer
- Phase
- Phase 1
- Started
- 2024-01
- Posted
- Registry
- NCT06179069
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 14 listed hospitals as study sitesBeijing, Changsha, Chengdu, Guangzhou, Harbin, Hefei, Nanchang, Nanjing, Shanghai, Shenyang, Wuhan, Xi'an, Xiamen, Zhengzhou
- RecruitingD-1553 Tablet Versus Docetaxel Injection for KRAS G12C Mutation-positive Locally Advanced or Metastatic Non-small Cell Lung Cancer After Prior Standard Therapy Failure
- Phase
- Phase 3
- Started
- 2024-03
- Posted
- Registry
- NCT06300177
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 63 listed hospitals as study sitesAnyang, Beijing, Changchun, Changsha, Changzhou, Chengdu, Chongqing, Fuzhou, Guangzhou, Guilin, Haikou, Hangzhou, Harbin, Hefei, Jinan, Kunming, Lanzhou, Luoyang, Nanchang, Nanjing, Nanning, Nantong, Shanghai, Shenyang, Shijiazhuang, Taiyuan, Tianjin, Urumqi, Weifang, Wenzhou, Wuhan, Wuxi, Xi'an, Xiamen, Xinxiang, Xuzhou, Zhanjiang, Zhengzhou, Zunyi
- RecruitingA Phase Ib/II Clinical Study of GH21 Capsules Combined With Osimertinib Mesylate Tablets in Patients With NSCLC
- Phase
- Phase 1/Phase 2
- Started
- 2024-03
- Posted
- Registry
- NCT06306456
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 6 listed hospitals as study sitesChangsha, Hefei, Nanjing, Shanghai, Taizhou, Zhengzhou
- RecruitingA Study of Calderasib (MK-1084) Plus Pembrolizumab (MK-3475) in Participants With KRAS G12C Mutant Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥50% (MK-1084-004/KANDLELIT-004)
- Phase
- Phase 3
- Started
- 2024-05
- Posted
- Registry
- NCT06345729
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 36 listed hospitals as study sitesBeijing, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Hangzhou, Harbin, Hefei, Jinan, Linyi, Nanchang, Nanjing, Shanghai, Suzhou, Taiyuan, Taizhou, Urumqi, Wenzhou, Wuhan, Wuxi, Xi'an, Xiamen, Zhengzhou
- RecruitingA Phase 1/2 Study of BGB-B2033, Alone or in Combination With Tislelizumab With or Without Bevacizumab, in Participants With Advanced or Metastatic Solid Tumors
- Phase
- Phase 1/Phase 2
- Started
- 2024-07
- Posted
- Registry
- NCT06427941
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 15 listed hospitals as study sitesChangsha, Chengdu, Chongqing, Guangzhou, Hangzhou, Harbin, Hefei, Nanchang, Nanning, Shijiazhuang, Wenzhou, Wuhan, Xuzhou
- RecruitingHypofractionated Radiotherapy Combined with Immunotherapy for Limited-stage Small-cell Lung Cancer
- Phase
- Phase 1/Phase 2
- Started
- 2024-07
- Posted
- Registry
- NCT06527898
Age 18 years to 70 years (registered criteria)
Led by First Affiliated Hospital of USTCHefei
- RecruitingA Phase III Study Comparing Taletrectinib With Standard Therapy in ROS1 Positive Locally Advanced or Metastatic Non-small Cell Lung Cancer Patients
- Phase
- Phase 3
- Started
- 2024-11
- Posted
- Registry
- NCT06564324
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 28 listed hospitals as study sitesBeijing, Changsha, Chengdu, Chongqing, Guangzhou, Hangzhou, Hefei, Jinan, Kunming, Linyi, Nanchang, Nanjing, Nanning, Shanghai, Shenyang, Shijiazhuang, Suzhou, Taiyuan, Tianjin, Wuhan, Xi'an, Xiamen, Zhengzhou
- RecruitingStudy of IBI3009 in Participants with Unresectable, Metastatic or Extensive-Stage Small Cell Lung Cancer
- Phase
- Phase 1
- Started
- 2024-12
- Posted
- Registry
- NCT06613009
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 7 listed hospitals as study sitesChangsha, Fuzhou, Hangzhou, Hefei, Jinan, Nanchang, Zhengzhou
- RecruitingLow Dose Radiotherapy Combined With Sintilimab and Chemotherapy as Neoadjuvant Therapy for Stage II-III NSCLC
- Phase
- Phase 2
- Started
- 2024-11
- Posted
- Registry
- NCT06714708
Age 18 years to Not stated (registered criteria)
Led by Anhui Provincial Cancer Hospital; 1 listed hospital as study siteHefei
- RecruitingA Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Participants With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers (CodeBreaK 202)
- Phase
- Phase 3
- Started
- 2023-11
- Posted
- Registry
- NCT05920356
Age 18 years to 100 years (registered criteria)
Lead sponsor is not a listed hospital; 45 listed hospitals as study sitesAnyang, Beijing, Bengbu, Changchun, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Hangzhou, Harbin, Hefei, Jinan, Kunming, Linyi, Luoyang, Nanchang, Nanjing, Nanning, Nantong, Shanghai, Shantou, Shijiazhuang, Taiyuan, Taizhou, Tianjin, Weifang, Wuhan, Xi'an, Xiamen, Xiangyang, Zhengzhou
- RecruitingPhase 3 Study of Toripalimab Alone or in Combination With Tifcemalimab as Consolidation Therapy in Patients With Limited-stage Small Cell Lung Cancer (LS-SCLC)
- Phase
- Phase 3
- Started
- 2023-11
- Posted
- Registry
- NCT06095583
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 28 listed hospitals as study sitesAnyang, Beijing, Changchun, Changsha, Chengdu, Chongqing, Guangzhou, Hangzhou, Harbin, Hefei, Jinan, Nanchang, Qingdao, Shanghai, Shenyang, Shenzhen, Taiyuan, Taizhou, Tianjin, Wuhan, Xiamen, Yinchuan, Zhengzhou
- RecruitingSacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab Versus Pembrolizumab Alone in Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥ 50% (MK-2870-007)
- Phase
- Phase 3
- Started
- 2023-12
- Posted
- Registry
- NCT06170788
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 29 listed hospitals as study sitesBeijing, Changsha, Chengdu, Fuzhou, Guangzhou, Hangzhou, Harbin, Hefei, Jinan, Nanchang, Shanghai, Shijiazhuang, Taizhou, Wuhan, Wuxi, Xiamen, Xiangyang, Xuzhou, Zhanjiang, Zhengzhou
- RecruitingOral Metronomic Vinorelbine and PD-1 Inhibitors in Elderly Non-small Cell Lung Cancer
- Phase
- Not given
- Started
- 2023-06
- Posted
- Registry
- NCT07041320
Age 65 years to Not stated (registered criteria)
Led by Anhui Chest HospitalHefei
- RecruitingA Study to Assess Disease Activity and Adverse Events of Intravenous (IV) Telisotuzumab Vedotin Compared to IV Docetaxel in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC)
- Phase
- Phase 3
- Started
- 2022-03
- Posted
- Registry
- NCT04928846
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 41 listed hospitals as study sitesBeijing, Changchun, Changsha, Chengdu, Chongqing, Dalian, Fuzhou, Guangzhou, Hangzhou, Harbin, Hefei, Hohhot, Jinan, Kunming, Linyi, Nanchang, Nanjing, Nanning, Nantong, Shanghai, Shantou, Shenyang, Shijiazhuang, Taiyuan, Taizhou, Tianjin, Urumqi, Wuhan, Xi'an, Xiamen, Zhanjiang, Zhengzhou
- RecruitingPhase 1/2a Study of JAB-21822 Plus JAB-3312 in Patients With Advanced Solid Tumors Harboring KRAS p.G12C Mutation
- Phase
- Phase 1/Phase 2
- Started
- 2022-04
- Posted
- Registry
- NCT05288205
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 24 listed hospitals as study sitesBeijing, Changsha, Fuzhou, Guangzhou, Harbin, Hefei, Hohhot, Jinan, Linyi, Shanghai, Shenyang, Shenzhen, Wuhan, Xiamen, Zhengzhou
- RecruitingAdjuvant Treatment Based on MRD for EGFR Mutant NSCLC
- Phase
- Phase 2
- Started
- 2022-09
- Posted
- Registry
- NCT05536505
Age 18 years to 80 years (registered criteria)
Lead sponsor is not a listed hospital; 15 listed hospitals as study sitesBeijing, Chongqing, Foshan, Fuzhou, Guangzhou, Hangzhou, Hefei, Qingdao, Shanghai, Shenzhen, Wuhan, Xiamen, Zhongshan
- RecruitingStudy of MCLA-129, a Human Bispecific EGFR and cMet Antibody, in Patients With Advanced NSCLC and Other Solid Tumors
- Phase
- Phase 1/Phase 2
- Started
- 2021-09
- Posted
- Registry
- NCT04930432
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 56 listed hospitals as study sitesBeijing, Bengbu, Changchun, Changsha, Chengdu, Chongqing, Dalian, Fuzhou, Guangzhou, Hangzhou, Harbin, Hefei, Jinan, Kunming, Lanzhou, Nanchang, Nanjing, Nanning, Nantong, Qingdao, Shanghai, Shantou, Shenyang, Shenzhen, Shijiazhuang, Suzhou, Taiyuan, Taizhou, Tianjin, Weifang, Wenzhou, Wuhan, Xi'an, Xiamen, Xuzhou, Yantai, Zhengzhou
- RecruitingPhase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7
- Phase
- Phase 2/Phase 3
- Started
- 2020-12
- Posted
- Registry
- NCT04613596
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 30 listed hospitals as study sitesBeijing, Bengbu, Changchun, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Hangzhou, Harbin, Hefei, Jinan, Linyi, Nanchang, Nanning, Shanghai, Shenyang, Shenzhen, Shijiazhuang, Taiyuan, Taizhou, Wuhan, Xi'an, Xiamen, Zhengzhou
- RecruitingAssessment of Anti-tumor and Safety in Glumetinib in Patients With c-MET-positive Non-Small Cell Lung Cancer
- Phase
- Phase 1/Phase 2
- Started
- 2019-07
- Posted
- Registry
- NCT04270591
Age 18 years to 80 years (registered criteria)
Lead sponsor is not a listed hospital; 23 listed hospitals as study sitesBeijing, Changchun, Changsha, Chengdu, Guangzhou, Hangzhou, Harbin, Hefei, Jinan, Nanchang, Nanjing, Shanghai, Shenyang, Shijiazhuang, Tianjin, Wuhan, Zhengzhou
- RecruitingSegmentectomy Versus Lobectomy for Lung Adenocarcinoma ≤ 2cm
- Phase
- N/A
- Started
- 2019-10
- Posted
- Registry
- NCT04937283
Age 20 years to 79 years (registered criteria)
Led by Shanghai Pulmonary Hospital; 8 listed hospitals as study sitesHangzhou, Hefei, Nantong, Ningbo, Shanghai, Xuzhou
- Not yet recruitingBecotatug Vedotin Combined With Pucotenlimab ± Radiotherapy as First-Line Treatment for Driver-Gene-Negative, EGFR-Expression-Positive Advanced Non-Small Cell Lung Cancer
- Phase
- Phase 2
- Started
- 2026-07
- Posted
- Registry
- NCT07627321
Age 18 years to 75 years (registered criteria)
Led by Anhui Provincial Cancer Hospital; 1 listed hospital as study siteHefei
- Not yet recruitingA Prospective Study of Firmonertinib as First-line Adaptive Therapy Guided by Dynamic ctDNA (MRD) Changes in Locally Advanced or Metastatic EGFR-mutated Non-small Cell Lung Cancer
- Phase
- Phase 2
- Started
- 2026-06
- Posted
- Registry
- NCT07661173
Age 18 years to Not stated (registered criteria)
Led by Anhui Provincial Cancer Hospital; 1 listed hospital as study siteHefei
- Not yet recruitingJS212 in Combination With JS111 as First-Line Treatment in EGFR-Mutant Advanced NSCLC
- Phase
- N/A
- Started
- 2026-07
- Posted
- Registry
- NCT07714304
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 2 listed hospitals as study sitesHefei, Shanghai
- Not yet recruitingStudy of MCLA-129 in the Treatment of Advanced Non-small Cell Lung Cancer with AGA and MET Amplification.
- Phase
- Phase 2
- Started
- 2025-03
- Posted
- Registry
- NCT06885840
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 17 listed hospitals as study sitesBeijing, Changchun, Changsha, Foshan, Guangzhou, Hangzhou, Harbin, Hefei, Jinan, Lanzhou, Shenyang, Tianjin, Wuhan, Xi'an, Zhengzhou
- Not yet recruitingYK-029A as First-Line Treatment Versus Platinum-Based Chemotherapy for Non-Small Cell Lung Cancer (NSCLC) With EGFR Exon 20 Insertion Mutations
- Phase
- Phase 3
- Started
- 2023-05
- Posted
- Registry
- NCT05767892
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 41 listed hospitals as study sitesBeijing, Bengbu, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Hangzhou, Harbin, Hefei, Hohhot, Jinan, Kunming, Luoyang, Nanchang, Nanjing, Qingdao, Shanghai, Shenyang, Shijiazhuang, Suzhou, Taiyuan, Taizhou, Tianjin, Wuhan, Xi'an, Xiamen, Zhengzhou
- Not yet recruitingA Study of AK104/Tislelizumab With Chemotherapy as First-line Treatment in PD-L1 TPS < 1% Non-small Cell Lung Cancer
- Phase
- Phase 3
- Started
- 2023-11
- Posted
- Registry
- NCT05990127
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 41 listed hospitals as study sitesBeijing, Bengbu, Changchun, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Hangzhou, Harbin, Hefei, Jinan, Kunming, Luoyang, Nanchang, Qingdao, Shanghai, Shenyang, Shijiazhuang, Suzhou, Taiyuan, Tianjin, Urumqi, Wuhan, Xi'an, Xinxiang, Xuzhou, Yinchuan, Zhengzhou
Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.
Disease research in Hefei
Each number is papers led on that disease, 2021–2025. “Open” counts open trials the hospital leads. Hospitals A–Z; this is not a ranking.
A blank cell means no papers or trials were found in these records. It does not mean the hospital does not treat that disease.
| Cancer | Blood disorders | Other diseases | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Hospital | Nasopharyngeal carcinoma | Oesophageal squamous cell carcinoma | Hepatocellular carcinoma | Stomach cancer | Lung cancer | Pancreatic cancer | Breast cancer | Glioma | Hepatoblastoma | Retinoblastoma | Chordoma | Osteosarcoma | Gastrointestinal stromal tumour | Neuroblastoma | Ewing sarcoma | Multiple myeloma | B-cell acute lymphoblastic leukaemia | Aplastic anaemia | Haemophagocytic lymphohistiocytosis | Lymphoma | Beta thalassaemia | Haemophilia A | Atypical haemolytic uraemic syndrome | Thrombotic thrombocytopenic purpura | Fanconi anaemia | Neuromyelitis optica spectrum disorder | IgG4-related disease | Myasthenia gravis | Moyamoya disease | Wilson disease | Biliary atresia | Coronary heart disease | Congenital heart disease | Scoliosis | Anti-NMDA receptor encephalitis | Takayasu arteritis | Hepatic echinococcosis | Idiopathic pulmonary fibrosis | Lymphangioleiomyomatosis | Amyotrophic lateral sclerosis | Spinal muscular atrophy | Fabry disease | Pompe disease | Duchenne muscular dystrophy | Behçet disease | Alport syndrome | IgA nephropathy | Gaucher disease | Niemann–Pick disease type C | Osteogenesis imperfecta | Primary biliary cholangitis | Primary sclerosing cholangitis | Congenital diaphragmatic hernia | Hirschsprung disease | Inherited epidermolysis bullosa | Hereditary angioedema | Familial adenomatous polyposis | Leber hereditary optic neuropathy | Majeed syndrome | NGLY1 deficiency | ISG15 deficiency | Shortlist |
| Affiliated Hospital, Anhui University of Chinese Medicine安徽中医药大学神经病学研究所附属医院 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | 4 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | |
| Anhui Chest Hospital安徽省胸科医院 | none | none | none | none | 16 | none | none | none | none | none | none | 1 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | 0 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | |
| Anhui Chest Hospital | none | none | none | none | 11 open | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | |
| Anhui Provincial Cancer Hospital安徽省肿瘤医院 | none | 0 | none | 0 | 1 | 0 | 0 | none | none | none | none | 0 | none | none | none | 0 | none | none | none | 0 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | 0 | none | none | none | none | none | none | none | none | none | |
| Anhui Provincial Children's Hospital安徽省儿童医院 | none | none | none | none | none | none | none | none | 1 | 1 | none | none | none | 8 | none | none | 1 | none | none | none | none | 0 | none | none | none | none | none | none | none | none | 2 | none | 3 | none | none | none | none | none | none | none | 0 | 0 | none | none | none | none | none | none | none | none | none | none | none | 1 | none | none | 0 | none | none | none | none | |
| First Affiliated Hospital of Anhui Medical University安徽医科大学第一附属医院 | 3 | 23 | 101 | 84 | 82 | 25 | 67 | 32 | none | 0 | none | 13 | 0 | 1 | 1 | 10 | none | 1 | none | 9 | none | none | none | 2 | 1 | none | none | 4 | none | 1 | none | 22 | 8 | none | 7 | 2 | none | 5 | none | none | none | none | none | 0 | none | none | 11 | none | 0 | none | 3 | 2 | 0 | 1 | 2 | none | 0 | 1 | none | none | none | |
| First Affiliated Hospital of Anhui University of Chinese Medicine安徽中医药大学第一附属医院 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | 52 | none | none | none | none | none | none | none | none | none | 2 | none | none | none | none | none | none | 5 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | |
| First Affiliated Hospital of USTC中国科学技术大学附属第一医院(安徽省立医院) | 2 | 176 open | 914 open | 22 | 682 open | 20 | 52 | 44 | none | none | none | 3 | 4 | 4 | none | 22 open | 12 open | 21 open | none | 133 open | none | 2 | none | 1 | 0 | 0 | none | 1 | 5 | 6 | none | 18 | 6 | none | 0 | none | none | 2 | 1 | 1 | none | 2 | none | none | 0 | 1 | 1 | none | none | none | 0 | 0 | 0 | 1 | none | none | none | none | none | none | none | |
| Fourth Affiliated Hospital of Anhui Medical University安徽医科大学第四附属医院 | none | none | none | none | none | none | none | none | none | none | none | 0 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | 0 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | |
| Hefei Binhu Hospital合肥市第一人民医院滨湖院区 | none | none | none | none | none | none | none | none | none | none | none | 0 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | |
| Hefei BOE Hospital合肥京东方医院 | none | none | none | none | none | none | none | none | none | none | none | 1 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | |
| Hefei Maternal and Child Health Hospital合肥市妇幼保健院 | none | none | none | none | none | none | none | none | none | none | none | none | none | 1 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | |
| Internet Hospital平安(合肥)互联网医院 | none | none | none | none | none | none | none | none | none | none | none | 0 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | |
| Police Forces Anhui Provincial Corps Hospital武警安徽省总队医院 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | 1 | none | none | none | none | none | none | none | none | none | |
| Second Affiliated Hospital of Anhui Medical University安徽医科大学第二附属医院 | none | 1 | 27 | 21 | 28 | 3 | 381 open | 17 | none | 1 | none | 6 | 1 | 2 | 1 | 7 | 4 | none | 1 | 16 | none | 4 | none | 1 | none | 2 | none | none | none | none | none | none | none | none | none | none | none | 4 | none | none | none | none | none | none | none | none | 0 | none | none | none | 1 | none | none | none | none | none | none | none | none | none | none | |
| South District Binhu Hospital合肥市第一人民医院南区 | none | none | none | none | none | none | none | none | none | none | none | none | none | 1 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | |
| Third Affiliated Hospital of Anhui Medical University合肥市第一人民医院 | none | none | none | none | none | none | none | none | none | none | none | 1 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | |
Column labels are short names. Choose one to open that disease in Hefei.
- Nasopharyngeal carcinoma 3
- Oesophageal squamous cell carcinoma 23
- Hepatocellular carcinoma 101
- Stomach cancer 84
- Lung cancer 82
- Pancreatic cancer 25
- Breast cancer 67
- Glioma 32
- Retinoblastoma 0
- Osteosarcoma 13
- Gastrointestinal stromal tumour 0
- Neuroblastoma 1
- Ewing sarcoma 1
- Multiple myeloma 10
- Aplastic anaemia 1
- Lymphoma 9
- Thrombotic thrombocytopenic purpura 2
- Fanconi anaemia 1
- Myasthenia gravis 4
- Wilson disease 1
- Coronary heart disease 22
- Congenital heart disease 8
- Anti-NMDA receptor encephalitis 7
- Takayasu arteritis 2
- Idiopathic pulmonary fibrosis 5
- Duchenne muscular dystrophy 0
- IgA nephropathy 11
- Niemann–Pick disease type C 0
- Primary biliary cholangitis 3
- Primary sclerosing cholangitis 2
- Congenital diaphragmatic hernia 0
- Hirschsprung disease 1
- Inherited epidermolysis bullosa 2
- Familial adenomatous polyposis 0
- Leber hereditary optic neuropathy 1
- Nasopharyngeal carcinoma 2
- Oesophageal squamous cell carcinoma 176 open
- Hepatocellular carcinoma 914 open
- Stomach cancer 22
- Lung cancer 682 open
- Pancreatic cancer 20
- Breast cancer 52
- Glioma 44
- Osteosarcoma 3
- Gastrointestinal stromal tumour 4
- Neuroblastoma 4
- Multiple myeloma 22 open
- B-cell acute lymphoblastic leukaemia 12 open
- Aplastic anaemia 21 open
- Lymphoma 133 open
- Haemophilia A 2
- Thrombotic thrombocytopenic purpura 1
- Fanconi anaemia 0
- Neuromyelitis optica spectrum disorder 0
- Myasthenia gravis 1
- Moyamoya disease 5
- Wilson disease 6
- Coronary heart disease 18
- Congenital heart disease 6
- Anti-NMDA receptor encephalitis 0
- Idiopathic pulmonary fibrosis 2
- Lymphangioleiomyomatosis 1
- Amyotrophic lateral sclerosis 1
- Fabry disease 2
- Behçet disease 0
- Alport syndrome 1
- IgA nephropathy 1
- Primary biliary cholangitis 0
- Primary sclerosing cholangitis 0
- Congenital diaphragmatic hernia 0
- Hirschsprung disease 1
- Oesophageal squamous cell carcinoma 1
- Hepatocellular carcinoma 27
- Stomach cancer 21
- Lung cancer 28
- Pancreatic cancer 3
- Breast cancer 381 open
- Glioma 17
- Retinoblastoma 1
- Osteosarcoma 6
- Gastrointestinal stromal tumour 1
- Neuroblastoma 2
- Ewing sarcoma 1
- Multiple myeloma 7
- B-cell acute lymphoblastic leukaemia 4
- Haemophagocytic lymphohistiocytosis 1
- Lymphoma 16
- Haemophilia A 4
- Thrombotic thrombocytopenic purpura 1
- Neuromyelitis optica spectrum disorder 2
- Idiopathic pulmonary fibrosis 4
- IgA nephropathy 0
- Primary biliary cholangitis 1
Other cities nearby
Straight-line distance from the city centre; counts are hospitals listed for lung cancer.
Counts are listed hospitals only, not every hospital in each city.
Where these numbers come from
Papers
English-language PubMed papers, 2021–2025, where the first or last author lists the hospital first. Definitions
Trials
ClinicalTrials.gov records with the hospital as lead sponsor or site, as of 8 Nov 2026. Search Hefei on ClinicalTrials.gov
Locations
Locations are shown at city centres. Check the hospital’s website for its address.